- Home
- VTGN vs IPSC Comparison
VTGN vs IPSC Comparison
Compare VTGN & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- IPSC
- Stock Information
- Founded
- VTGN 1998
- IPSC 2019
- Country
- VTGN United States
- IPSC United States
- Employees
- VTGN N/A
- IPSC N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- VTGN Health Care
- IPSC Health Care
- Exchange
- VTGN Nasdaq
- IPSC Nasdaq
- Market Cap
- VTGN 81.3M
- IPSC 88.4M
- IPO Year
- VTGN N/A
- IPSC 2021
- Fundamental
- Price
- VTGN $2.92
- IPSC $0.91
- Analyst Decision
- VTGN
- IPSC Strong Buy
- Analyst Count
- VTGN 0
- IPSC 4
- Target Price
- VTGN N/A
- IPSC $11.00
- AVG Volume (30 Days)
- VTGN 401.9K
- IPSC 562.3K
- Earning Date
- VTGN 02-11-2025
- IPSC 03-13-2025
- Dividend Yield
- VTGN N/A
- IPSC N/A
- EPS Growth
- VTGN N/A
- IPSC N/A
- EPS
- VTGN N/A
- IPSC N/A
- Revenue
- VTGN $876,000.00
- IPSC $2,684,000.00
- Revenue This Year
- VTGN N/A
- IPSC $230.56
- Revenue Next Year
- VTGN N/A
- IPSC $31.85
- P/E Ratio
- VTGN N/A
- IPSC N/A
- Revenue Growth
- VTGN 8.08
- IPSC 7.88
- 52 Week Low
- VTGN $2.22
- IPSC $0.87
- 52 Week High
- VTGN $5.74
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- VTGN 53.24
- IPSC 33.31
- Support Level
- VTGN $2.40
- IPSC $0.87
- Resistance Level
- VTGN $3.40
- IPSC $1.19
- Average True Range (ATR)
- VTGN 0.21
- IPSC 0.09
- MACD
- VTGN -0.00
- IPSC -0.00
- Stochastic Oscillator
- VTGN 47.83
- IPSC 12.75
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.